

FUNDED PROJECTS KWF PROGRAMME RESEARCH & IMPLEMENTATION CALL 2016-I

RESEARCH PROJECTS

Project Number	Project Title	Project Leader	Institute	Department	Research Phase	Mission Goal(s)	Tumor type	Assigned Funder	Approved budget
10150	The Achilles' Heel of mesenchymal colon cancers	Prof. Jan Paul Medema	Academic Medical Center	Center of Experimental and Molecular Medicine	Basic research	Basic Research; More Cure	Colon and Rectal Cancer		€ 1.169.422.00
10275	Targeting bone marrow retention to provoke homelessness of the tumor cells as a strategy to cure Multiple Myeloma	Dr. Marcel Spaargaren	Academic Medical Center	Pathology	Credentialing	Basic Research; More Cure	Leukemia ;Myeloma;Non-Hodgkin's Lymphoma		€ 551.055.00
10510	Genetic properties of breast carcinomas associated with cancer-immune interactions	Prof. Marc van de Vijver	Academic Medical Center	Pathology	Credentialing	Basic Research; More Cure; Better Quality of Life	Breast Cancer		€ 721.382.00
10113	Child-tailored image guided adaptive radiotherapy: because children are not adults.	Dr. Arjan Bel	Academic Medical Center	Radiation Oncology (Radiotherapy)	Clinical	More Cure; Better Quality of Life	Neuroblastoma;Not Site-Specific Cancer;Sarcoma (soft tissue)		€ 455.015.50
10274	Evaluation of optimal intervals for colonoscopy surveillance: a randomized trial	Prof. Evelien Dekker	Academic Medical Center	Gastroenterology and Hepatology	Clinical	Less cancer; Better Quality of Life	Colon and Rectal Cancer		€ 1.142.391.50
10324	Randomized phase-II trial of obinutuzumab, obinutuzumab and venetoclax and standard or MRD guided venetoclax maintenance in first-line patients with CLL	Prof. Arnon Kater	Academic Medical Center	Clinical Haematology	Clinical	More Cure; Better Quality of Life	Leukemia		€ 266.695.00
10460	Something old, something new: Repurposing already-approved metabolic drugs to target IDH1/2 mutations in cancer	Dr. Johanna Wilmink	Academic Medical Center	Oncology	Clinical	More Cure	Brain Tumor;Gastrointestinal Tract;Liver Cancer;Nervous System;Sarcoma (soft tissue)	Alpe d'HuZes	€ 181.137.00
10495	NUTritional Route In Esophageal resection Trial II (NUTRIENT II)	Dr. Misha Luyer	Catharina Ziekenhuis Eindhoven	Surgery	Clinical	More Cure; Better Quality of Life	Oesophageal Cancer	Alpe d'HuZes	€ 309.225.27
10506	New insights in the DNA damage response to anti-cancer platinum drugs	Prof. Wim Vermeulen	Erasmus University Medical Center Rotterdam	Genetics	Basic research	Basic Research; More Cure; Better Quality of Life	Not Site-Specific Cancer		€ 533.637.00
10270	The role of APOBEC3B in breast cancer therapy resistance	Dr. John Martens	Erasmus University Medical Center Rotterdam	Medical Oncology	Credentialing	Basic Research; More Cure	Breast Cancer		€ 570.802.50
10317	Hitting the prostate cancer cell via PSMA-targeted radiotherapy: safer and better	Prof. Marion de Jong	Erasmus University Medical Center Rotterdam	Radiology / Nuclear Medicine	Preclinical	More Cure	Prostate Cancer		€ 590.896.40
10246	Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma	Dr. Eva Madsen	Erasmus University Medical Center Rotterdam	Surgery	Clinical	More Cure; Better Quality of Life	Gastrointestinal Tract		€ 599.996.65
10319	REduce BIAgger Cancer REcurrence in Patients Treated for Upper Urinary Tract Urothelial Carcinoma: the REBACARE trial	Dr. Joost Boormans	Erasmus University Medical Center Rotterdam	Urology (Sophia)	Clinical	Less Cancer; More Cure	Bladder Cancer;Urinary System		€ 439.720.70
10320	Phase II study evaluating the feasibility and efficacy of predefined de-escalating and -escalating G-CHOP in elderly patients, with DLBCL	Dr. Pieterella Lugtenburg	Erasmus University Medical Center Rotterdam	Hematology	Clinical	More Cure; Better Quality of Life	Non-Hodgkin's Lymphoma		€ 1.309.000.00
10516	Adjuvant hepatic arterial infusion pump chemotherapy after complete resection of colorectal liver metastases – a randomized controlled trial.	Dr. Bas Groot Koerkamp	Erasmus University Medical Center Rotterdam	Surgery	Clinical	More Cure; Better Quality of Life	Colon and Rectal Cancer;Liver Cancer		€ 589.494.20
10126	Exploring the impact of diverse chromosomal instability levels on tumour progression and disease remission	Dr. Nannette Jelluma	Hubrecht Institute	Hubrecht Institute (department)	Basic research	Basic Research;Less Cancer;More Cure	Not Site-Specific Cancer		€ 790.792.00
10158	Quantifying clonal dynamics, metastatic potential and therapy resistance in breast cancer organoids using single-cell sequencing	Prof. Alexander van Oudenaarden	Hubrecht Institute	Hubrecht Institute (department)	Basic research	Basic Research	Breast Cancer		€ 501.907.00
10168	Tumour-specific immunity in vulvar carcinoma and its impact on survival	Dr. Mariëtte van Poelgeest	Leiden University Medical Center	Gynaecology	Basic research	Basic Research	Vulva Cancer		€ 602.280.00
10208	Oncogenic B-Cell Receptor Signalling in Aggressive B-Cell Lymphomas	Prof. Hendrik Veelken	Leiden University Medical Center	Hematology	Basic research	Basic Research; More Cure	Hodgkin's Disease; Non-Hodgkin's Lymphoma		€ 339.488.00
10174	Chemotherapy or not? Practice changing approach for the selection of patients for accurate chemotherapy treatment after colon cancer diagnosis.	Dr. Wilma Mesker	Leiden University Medical Center	Surgery (Oncology)	Preclinical	More Cure; Better Quality of Life	Colon and Rectal Cancer	Alpe d'HuZes	€ 625.627.70
10473	HOlmium radioembolization as adjuvant treatment to Radiofrequency Ablation for Early STage Hepatocellular carcinoma (HORA EST HCC): a dose-finding study	Dr. Arian Van Erkel	Leiden University Medical Center	Radiology	Clinical	Less cancer; More Cure; Better Quality of Life	Liver Cancer		€ 257.367.90
10089	Standardizing TrAining for endoscopic Resection of Large Non-Pedunculated Colorectal Polyps: it is prime-time to change practice (*STAR-LNPCP)	Dr. Silvia Sanduleanu	Maastricht UMC+ (Maastricht University)	GROW, School for Oncology and Developmental Biology	Clinical	Less cancer; More Cure; Better Quality of Life	Colon and Rectal Cancer		€ 399.418.90

10354	Cooperative and mutually exclusive genetic alterations in pediatric cancer	Dr. Patrick Kemmeren	Princess Maxima Center for Pediatric Oncology	Research Operations	Basic research	Basic Research	Not Site-Specific Cancer		€	572.050.00
10355	Identification of biomarkers by whole-genome sequencing and phospho-proteomics to predict responses to high-precision cancer medicines in T-cell acute lymphoblastic leukemia	Dr. Jules Meijerink	Princess Maxima Center for Pediatric Oncology	Research Operations	Credentialing	More Cure; Better Quality of Life	Leukemia		€	655.556.00
10482	Beating chromosome 21: small chromosome, large consequences in acute lymphoblastic leukemia	Dr. Judith Boer	Princess Maxima Center for Pediatric Oncology	Research Operations	Credentialing	More Cure	Leukemia		€	593.382.50
10072	Breaking therapy resistance in IKZF1 deleted Acute Lymphoblastic Leukemia	Dr. Frank van Leeuwen	Radboud University Medical Center	Paediatrics	Basic research	Basic Research; More Cure; Better Quality of Life	Leukemia		€	490.879.60
10289	Identify the patient and save the family – detecting hereditary pancreatic cancer	Prof. Iris Nagtegaal	Radboud University Medical Center	Pathology	Credentialing	Less Cancer; More Cure	Breast Cancer;Colon and Rectal Cancer;Melanoma ;Pancreatic Cancer		€	459.300.30
10443	Bimodal PSMA ligands for intra-operative tumor detection and photodynamic therapy of prostate cancer	Prof. Otto Boerman	Radboud University Medical Center	Radiology and Nuclear Medicine	Creation of modality	More Cure; Better Quality of Life	Prostate Cancer		€	584.055.00
10100	Intraperitoneal infusion of ex vivo-generated allogeneic natural killer cells in recurrent ovarian carcinoma patients: a phase I study	Dr. Harry Dolstra	Radboud University Medical Center	Laboratory Medicine	Clinical	More Cure	Ovarian Cancer		€	987.463.20
10128	Fluorescence image-guided surgery in patients with peritoneal carcinomatosis of colorectal origin	Dr. Mark Rijpkema	Radboud University Medical Center	Radiology and Nuclear Medicine	Clinical	More Cure	Colon and Rectal Cancer		€	567.865.00
10151	Impaired Spermatogenesis and Testosterone Deficiency in Male Survivors of Childhood Cancer: a DCOG-LATER study	Dr. Jacqueline Loonen	Radboud University Medical Center	Hematology	Clinical	Better Quality of Life	Brain Tumor;Kidney Cancer ;Leukemia ;Nervous System ;Neuroblastoma;Non-Hodgkin's Lymphoma; Sarcoma (soft tissue)		€	438.068.20
10224	Diagnostic accuracy of contrast enhanced diffusion weighted MRI for liver metastases of pancreatic cancer: towards adequate staging of pancreatic cancer	Dr. John J.J. Hermans	Radboud University Medical Center	Radiology and Nuclear Medicine	Clinical	Basic Research	Pancreatic Cancer		€	692.147.95
10132	Potentiating autologous T cell therapy by driving continuous IFN γ production within the tumor	Dr. Monika Wolkers	Sanquin Research	Hematopoiesis	Basic research	Basic Research; More Cure	Melanoma		€	627.445.00
10300	On the mechanism by which targeting CD47-SIRP α interactions potentiates antibody therapy in cancer	Dr. Timo K. van den Berg	Sanquin Research	Blood Cell Research	Basic research	Basic Research; More Cure; Better Quality of Life	Not Site-Specific Cancer		€	513.772.60
10032	Precision Cancer Therapy: Profiting from Tumor Specific Defects and Synthetic Lethality in the DNA Damage Tolerance System	Dr. Heinz Jacobs	The Netherlands Cancer Institute	Biological Stress Response	Basic research	Basic Research; More Cure	Not Site-Specific Cancer		€	962.986.50
10083	Enhancing the success of immunotherapy for metastatic breast cancer by overcoming tumor-associated immunosuppressive mechanisms	Dr. Karin de Visser	The Netherlands Cancer Institute	Immunology	Basic research	Basic Research; More Cure	Breast Cancer		€	557.591.50
10215	Membrane glycerophosphodiesterases: novel players in cell differentiation and cancer biology	Dr. Anastassis Perrakis	The Netherlands Cancer Institute	Biochemistry	Basic research	Basic Research	Not Site-Specific Cancer		€	497.637.00
10304	Increasing drug holiday impact on therapy-refractory cancers for more durable responses	Prof. Daniel Peeper	The Netherlands Cancer Institute	Molecular Oncology	Basic research	Basic Research; More Cure	Melanoma		€	565.911.00
10315	Diricore, a platform for the discovery of novel amino acid vulnerabilities in aggressive cancer	Prof. Reuven Agami	The Netherlands Cancer Institute	Biological Stress Response	Basic research	Basic Research; More Cure	Brain Tumor; Not Site-Specific Cancer		€	621.641.00
10425	Targeting phenotype switching as a therapy for melanoma	Prof. Daniel Peeper	The Netherlands Cancer Institute	Molecular Oncology	Basic research	Basic Research; More Cure	Melanoma		€	567.761.50
10138	Development and validation of a multiparametric imaging model for pre-treatment response prediction in rectal cancer: the road towards organ-preservation	Prof. Regina Beets-Tan	The Netherlands Cancer Institute	Diagnostic Oncology	Credentialing	Basic Research; More Cure; Better Quality of Life	Colon and Rectal Cancer;Gastrointestinal Tract		€	472.397.60
10164	Favorable and unfavorable effects of risk-reducing salpingo-oophorectomy (RRSO) in women at high genetic risk of ovarian cancer	Prof. Flora van Leeuwen	The Netherlands Cancer Institute	Psychosocial Research and Epidemiology	Credentialing	Less cancer; Better Quality of Life	Breast Cancer;Ovarian Cancer		€	791.172.10
10325	Does physical exercise during adjuvant cardiotoxic chemotherapy protect against cardiac injury among women with breast cancer?	Dr. Wim Groen	The Netherlands Cancer Institute	Psychosocial Research and Epidemiology	Credentialing	Better Quality of Life	Breast Cancer	Alpe d'HuZes	€	336.720.00
10424	Cardiotoxicity and second cancer risk after treatment of aggressive B-cell Non-Hodgkin Lymphoma	Mr. Michael Schaapveld	The Netherlands Cancer Institute	Psychosocial Research and Epidemiology	Credentialing	Less cancer; Better Quality of Life	Non-Hodgkin's Lymphoma	Alpe d'HuZes	€	747.568.00
10004	Statistical assessment of cancer risks from therapeutic radiation exposure incorporating the spatial distribution of radiation dose in the target organ	Dr. Michael Hauptmann	The Netherlands Cancer Institute	Psychosocial Research and Epidemiology	Creation of modality	Less cancer; Better Quality of Life	Brain Tumor;Breast Cancer Hodgkin's Disease;Leukemia ;Sarcoma (soft tissue)	Alpe d'HuZes	€	440.555.70
10438	Liquid biopsy analyses of cell-free circulating tumor DNA as predictive and prognostic biomarker for colorectal cancer patients with metastatic disease	Dr. Remond Fijneman	The Netherlands Cancer Institute	Diagnostic Oncology	Creation of modality	More Cure; Better Quality of Life	Colon and Rectal Cancer		€	1.033.588.00
10014	The Drug Rediscovery Protocol (DRUP trial)	Prof. Emile Voest	The Netherlands Cancer Institute	Molecular Oncology	Clinical	Better Quality of Life	Not Site-Specific Cancer		€	1.745.061.87

10084	Biomarker discovery for prognostication and treatment selection in prostate cancer through Androgen Receptor profiling	Dr. Wilbert Zwart	The Netherlands Cancer Institute	Molecular Pathology	Clinical	More Cure; Better Quality of Life	Prostate Cancer	Alpe d'HuZes	€	655.645.00
10088	Focal escalation of the radiation dose to the tumor in prostate cancer	Prof. Uulke van der Heide	The Netherlands Cancer Institute	Radiotherapy	Clinical	More Cure; Better Quality of Life	Prostate Cancer	Alpe d'HuZes	€	468.696.50
10094	CRADLE: Cancer tReAtment During pregnancy: from fetal safety to maternal Efficacy	Prof. Frédéric Amant	The Netherlands Cancer Institute	Medical Oncology	Clinical	More Cure; Better Quality of Life	Breast Cancer;Cervical Cancer;Hodgkin's Disease ;Leukemia ;Melanoma;Non-Hodgkin's Lymphoma		€	600.666.00
10513	Datamanagement for UM 2015-7738: Multicenter evaluation of the "wait-and-see" policy for complete responders after chemoradiotherapy for rectal cancer	Prof. Geerard Beets	The Netherlands Cancer Institute	Surgical oncology	Clinical	Better Quality of Life	Colon and Rectal Cancer		€	427.741.72
10123	The intermediate filament network in glioma invasion	Prof. Elly Hol	UMC Utrecht	Neurosciences	Basic research	Basic Research	Brain Tumor		€	493.975.60
10456	The Mutant Adhesome and the Progression of Lobular Breast cancer.	Dr. Patrick Derksen	UMC Utrecht	Laboratories & Pharmacy	Basic research	Basic Research; More Cure; Better Quality of Life	Breast Cancer		€	609.806.50
10471	Control of stem cell and cancer metabolism by PI3K/AKT/FOXO signaling	Prof. Boudewijn Burgering	UMC Utrecht	Biomedical Genetics	Basic research	Basic Research	Colon and Rectal Cancer; Not Site-Specific Cancer		€	619.552.00
10496	FOOTPRINT: Finding Oncogenic muTational PRocesses IN liver Tumorigenesis	Prof. Edwin Cuppen	UMC Utrecht	Biomedical Genetics	Basic research	Basic Research; Less Cancer	Liver Cancer		€	525.790.00
10366	Inner Centromere Integrity and Chromosomal INstability (CIN) in Cancer	Prof. Susanne Lens	UMC Utrecht	Biomedical Genetics	Basic research	Basic Research	Not Site-Specific Cancer		€	527.402.00
10474	Development of superior Wilms' tumor 1 specific gene modified CORD BLOOD T cells to treat refractory acute myeloid leukemia patients.	Dr. Nico van Til	UMC Utrecht	Laboratories & Pharmacy	Creation of modality	Basic Research; More Cure; Better Quality of Life	Leukemia		€	533.554.00
10291	Image-guided response assessment of neoadjuvant chemoradiotherapy for esophageal cancer patients	Dr. Gert Dr. Meijer	UMC Utrecht	UMC Utrecht Cancer Center	Clinical	More Cure; Better Quality of Life	Oesophageal Cancer	Alpe d'HuZes	€	623.809.50
10307	Holmium-166 microspheres for radioembolization in HCC patients: new generation microspheres for individualized treatment	Prof. Marnix Lam	UMC Utrecht	Imaging	Clinical	More Cure; Better Quality of Life	Liver Cancer		€	492.314.40
10080	Oncogenic functions of the transcription factor C/EBPβ in breast cancer	Prof. Cor Calkhoven	University Medical Center Groningen	Ageing Biology	Basic research	Basic Research; Less Cancer	Breast Cancer		€	660.445.00
10330	To enhance the efficacy of cancer immunotherapy by metabolic reprogramming tumour-associated immune suppressor cells	Prof. Toos Daemen	University Medical Center Groningen	Medical Microbiology	Credentialing	More Cure	Cervical Cancer;Ovarian Cancer		€	500.771.00
10477	Understanding why cancer patients experiencing depressive symptoms report no need for care	Dr. Maya Schroevers	University Medical Center Groningen	Health Sciences	Credentialing	Better Quality of Life	Not Site-Specific Cancer		€	340.425.60
10504	Non-invasive whole-body imaging of immune checkpoints using radiolabeled small molecules as predictive biomarker for response to therapy	Prof. Hans Nijman	University Medical Center Groningen	Obstetrics and Gynaecology	Creation of modality	More Cure	Not Site-Specific Cancer		€	839.863.00
10034	POINTING: Towards patient-tailored cancer immunotherapy supported by a multifaceted predictive signature composed of integrative omics and molecular imaging	Prof. Elisabeth de Vries	University Medical Center Groningen	Medical Oncology	Clinical	More Cure	Lung Cancer;Melanoma		€	1.988.916.70
10432	HOVON 138 / APOLLO	Prof. Edo Vellenga	University Medical Center Groningen	Hematology	Clinical	More Cure; Better Quality of Life	Leukemia		€	48.596.00
10212	INTERROGATING THE PHOSPHOPROTEOME FOR TARGETS AND MARKERS IN PANCREATIC CANCER	Dr. Connie Jimenez	VU University Medical Centre	Medical Oncology (VUmc CCA)	Basic research	Basic Research; More Cure; Better Quality of Life	Pancreatic Cancer		€	835.908.75
10449	Hijacking viral strategies to induce anti-pancreatic cancer immune responses: in vivo targeting of virus-like liposomes to CD169+ antigen presenting cells.	Dr. Joke den Haan	VU University Medical Centre	Molecular Cell Biology and Immunology (VUmc CCA)	Basic research	Basic Research; More Cure; Better Quality of Life	Pancreatic Cancer		€	460.831.00
10401	Evaluation of tumor-educated platelet profiles for screening and follow-up of pancreatic cancer	Dr. Elisa Giovannetti	VU University Medical Centre	Medical Oncology (VUmc CCA)	Credentialing	Less cancer; More Cure	Pancreatic Cancer		€	353.467.00
10476	Epi-transcriptomic small RNA modifications as predictive signatures for therapy response in Diffuse Large B cell Lymphoma	Dr. Danijela Koppers-Lalic	VU University Medical Centre	Neurosurgery (VUmc CCA)	Credentialing	Basic Research; More Cure; Better Quality of Life	Non-Hodgkin's Lymphoma		€	547.890.00
10382	Cancer risk assessment in women with vulvar intraepithelial neoplasia	Dr. Maaïke Bleeker	VU University Medical Centre	Pathology (VUmc CCA)	Preclinical	Less cancer; More Cure; Better Quality of Life	Vulva Cancer		€	461.982.00
10328	Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma	Dr. Martine Chamuleau	VU University Medical Centre	Hematology (VUmc CCA)	Clinical	More Cure; Better Quality of Life	Non-Hodgkin's Lymphoma	Alpe d'HuZes	€	713.954.00

Total funding Research Projects (71 projects): € 43.801.332.61

BAS MULDER AWARDS / YOUNG INVESTIGATOR GRANTS

Project Number	Project Title	Project Leader	Institute	Department	Research Phase	Mission Goal(s)	Tumor type	Assigned Funder	Approved budget
10140	Identification of tumor-initiating cells in liver cancer and their interactions with hepatitis viruses	Dr. Qiuwei Pan	Erasmus University Medical Center Rotterdam	Gastroenterology and Hepatology	Basic research	Basic Research; Less Cancer; More Cure	Liver Cancer	Alpe d'HuZes	€ 548.604.40
10321	Role of GATA2-controlled programs in the genetic predisposition to acute leukemia	Dr. Emma de Pater	Erasmus University Medical Center Rotterdam	Hematology	Basic research	Basic Research; Less Cancer; More Cure; Better Quality of Life	Leukemia	Alpe d'HuZes	€ 517.629.50
10418	Resolving the POLE paradox in Endometrial Cancer: "To treat or not to treat - that is the question".	Dr. Tjalling Bosse	Leiden University Medical Center	Pathology	Credentialing	Basic Research; Better Quality of Life	Endometrial Cancer	Alpe d'HuZes	€ 506.459.50
10392	Decreasing the burden of knowledge by improving communication with seriously ill breast cancer patients	Dr. Liesbeth van Vliet	NIVEL	Communication	Credentialing	Better Quality of Life	Breast Cancer	Alpe d'HuZes	€ 445.179.42
10218	Exploring high risk pediatric renal tumors in patient-derived kidney organoids	Dr. Jarno Drost	Princess Maxima Center for Pediatric Oncology	Research Operations	Basic research	Basic Research; More Cure	Kidney Cancer	Alpe d'HuZes	€ 517.654.20
10099	Towards personalized use of immune checkpoint inhibitors by imaging of the PD-1/PD-L1 pathway	Dr. Sandra Heskamp	Radboud University Medical Center	Radiology and Nuclear Medicine	Creation of modality	Basic Research; More Cure; Better Quality of Life	Not Site-Specific Cancer	Alpe d'HuZes	€ 656.250.00
10351	Boosting graft-versus-leukemia immunity by combining hypomethylating agents and immunotherapy in patients with acute myeloid leukemia	Dr. Willemijn Hobo	Radboud University Medical Center	Laboratory Medicine	Preclinical	More Cure	Leukemia	Alpe d'HuZes	€ 601.250.00
10267	Customized cord blood-derived dendritic cells to get better disease control in refractory childhood cancers	Dr. Maud Plantinga	UMC Utrecht	Laboratories & Pharmacy	Creation of modality	Basic Research; More Cure	Leukemia	Alpe d'HuZes	€ 478.511.40

Total funding Young Investigator Grants (8 projects): € 4.271.538.42

UNIQUE HIGH RISK PROJECTS

Project Number	Project Title	Project Leader	Institute	Department	Research Phase	Mission Goal(s)	Tumor type	Assigned Funder	Approved budget
10429	Developing a mass spectrometry-based screening method to identify targets for immunotherapy to cure and prevent hepatitis B-related liver cancer	Dr. Sonja Buschow	Erasmus University Medical Center Rotterdam	Gastroenterology and Hepatology	Credentialing	Basic Research; Less Cancer; Better Quality of Life	Liver Cancer	Alpe d'HuZes	€ 149.437.00
10436	Toward removing the UN from BRCA2 variants of UNknown significance: Importance of protein domains in conformational flexibility	Prof. Claire Wyman	Erasmus University Medical Center Rotterdam	Radiotherapy	Basic research	Basic Research; More cure	Breast Cancer; Ovarian Cancer	Alpe d'HuZes	€ 149.999.90
10222	HLA class I-restricted neoantigens as targets for immunotherapy of acute myeloid leukemia	Dr. Marieke Griffioen	Leiden University Medical Center	Hematology	Basic research	Basic Research; More Cure	Leukemia	Alpe d'HuZes	€ 150.640.50
10339	Blood vessel stabilization induced by targeting pericytes in cancer therapies	Dr. Franck Lebrin	Leiden University Medical Center	Internal medicine	Preclinical	More Cure	Brain Tumor ;Breast Cancer ;Colon and Rectal Cancer	Alpe d'HuZes	€ 150.000.00
10417	Prediction and modification of treatment response in esophageal cancer	Prof. John Plukker	University Medical Center Groningen	Medical Oncology	Preclinical	More Cure; Better Quality of Life	Oesophageal Cancer	Alpe d'HuZes	€ 146.214.50
10478	Exploring the role of long non-coding RNAs in B-cell lymphoma	Prof. Anke van den Berg	University Medical Center Groningen	Pathology and Medical Biology	Basic research	Basic Research	Hodgkin's Disease;Non-Hodgkin's Lymphoma	Alpe d'HuZes	€ 149.972.50
10491	Evaluating genomic heterogeneity at the single cell level as a predictor of response to treatment of NSCLC patients	Prof. Harry Groen	University Medical Center Groningen	Pulmonary Diseases	Basic research	Basic Research	Lung Cancer	Alpe d'HuZes	€ 151.361.60
10271	Chromorexis: Structure and clinical relevance of a newly discovered genome rearrangement phenomenon	Prof. Bauke Ylstra	VU University Medical Centre	Pathology (VUmc CCA)	Basic research	Basic Research	Not Site-Specific Cancer	Alpe d'HuZes	€ 182.999.90
10395	RNA modifying enzymes diversify the microRNA repertoire and function during early stage cancer development	Dr. Renske Steenbergen	VU University Medical Centre	Pathology (VUmc CCA)	Basic research	Basic Research; Less Cancer; Better Quality of Life	Not Site-Specific Cancer	Alpe d'HuZes	€ 158.240.00

Total Funding Unique High Risk Projects (9 projects): € 1.388.865.90

Total funding CALL 2016-I: € 49.461.736.93

OVERVIEW

Research tracks & research phases	Number of projects	Funding
Exploration track	50	€ 25.918.980.57
Basic research	33	€ 17.176.015.05
Credentialing	17	€ 8.742.965.52
Development track	38	€ 23.542.756.36
Creation of modality	7	€ 4.566.377.10
Preclinical	6	€ 2.575.970.60
Clinical	25	€ 16.400.408.66
Total	88	€ 49.461.736.93

Funding types & research phases	Number of projects	Funding
Research Projects	71	€ 43.801.332.61
Basic research	24	€ 14.648.912.55
Credentialing	14	€ 7.641.889.60
Creation of modality	5	€ 3.431.615.70
Preclinical	3	€ 1.678.506.10
Clinical	25	€ 16.400.408.66
Young Investigator Grants	8	€ 4.271.538.42
Basic research	3	€ 1.583.888.10
Credentialing	2	€ 951.638.92
Creation of modality	2	€ 1.134.761.40
Preclinical	1	€ 601.250.00
Unique High Risk Projects	9	€ 1.388.865.90
Basic research	6	€ 943.214.40
Credentialing	1	€ 149.437.00
Preclinical	2	€ 296.214.50
Total	88	€ 49.461.736.93